Periodic Reporting for period 2 - COL_RES (Colonization resistance: training and research towards microbiome derived solutions to foodborne disease)
Reporting period: 2023-03-01 to 2025-02-28
Every year there are an estimated 600 million cases of foodborne infection globally with 420,000 deaths. In the WHO European Region approximately 23 million people fall ill annually from foodborne infection with an estimated 4654 deaths. The impacts for society both globally and locally within the European Region, are clearly highly significant.
The overall objectives of COL_RES are to examine the mechanisms by which the gut microbiota protects against serious foodborne pathogens (Salmonella, E. coli, Listeria, Citrobacter rodentium and Campylobacter) in order to identify potential probiotics that can protect against individual or multiple infectious agents. The network employed a systems biology-based approach by exploiting a variety of research models at world-leading laboratories, combined with metabolomics, bioinformatics and phage therapeutics to generate multi-omics data that has uncovered mechanisms by which the gut microbiota protects against specific foodborne pathogens and has informed the development of model experimental systems. Throughout the collaborative research programme COL_RES provided state-of-the-art training for 8 early-stage researchers preparing them for problem solving and entrepreneurial roles in industry and society and underpinning cutting-edge research in infectious disease in the EU. All 8 ESRs have completed (or are due to complete) their PhD studies.
COL_RES ESRs have published 15 papers at the time of writing with numerous other manuscripts submitted or in-preparation. A collaboration based upon multiple secondments to ETH-Zürich has established a defined microbiota OligoMM12 mouse model as a significant model system for analysing our pathogens (published in Gut Microbes). The COL_RES programme provided further insights into the mechanisms that underpin colonization resistance against Campylobacter as well as Salmonella, Listeria and Enterohaemorrhagic E. coli (EHEC) infection (incl. papers in Nat. Commun, Frontiers in Microbiology, Eur. Journal of Microbiol & Immunol and Microbial Cell). The research has identified a number of potential probiotic strains that show promise in the inhibition of Salmonella, Campylobacter and Listeria. The work has also isolated novel bacteriophage (bacterial viruses) as potential therapeutics against both Listeria monocytogenes and Citrobacter. Other research breakthroughs have been made in the development of new computational tools for analysis of genetic and chemical (metabolite) data which will be of use to the international research community (incl. a paper in Analytical Chem).
The use of the above models allowed investigation of the impact of complex inflammatory processes on pathogenesis in the context of diet and sepsis. However, we also developed animal-free models of the human gut microbiota and provided insights into diet-associated and age-related changes to the microbiota which impact proliferation of EHEC (published in Nutrients (2024) and Microbial Cell (2025)) as well as Listeria (manuscripts in preparation) in such models.
Given the scientific (and societal) importance of big data analysis, our ESRs all received significant training in bioinformatics and data integration. This was facilitated through collaborative activities within the programme involving experts in bioinformatics and chemical analytics (metabolomics). ESRs working specifically in these fields have developed improved computational and analytical tools for chemical (metabolite) analysis (paper published in Analytical Chemistry (2024)), identification of bacterial species from genetic data (manuscript in preparation) and methods to analyse multicomponent datasets (paper in preparation).
Overall, the COL_RES programme has trained 8 PhD students to a high level through a cutting-edge research and training programme. Importantly we have identified potential probiotic and phage-mediated interactions which have the future potential to impact the significant human cost of foodborne disease (600 million infections per annum globally) to improve quality of life and decrease mortality from foodborne disease.